Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...
Hosted on MSN6m
Hims & Hers launches GLP-1 drug shortage trackerHims & Hers (NYSE:HIMS) has launched an online GLP-1 supply tracker where people can share information about where the ...
Weight loss drugs are incredibly sought-after, but they’re also often difficult to obtain due to limited insurance coverage ...
Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 ...
In a study of around 228,000 people in Sweden who had alcohol use disorder, researchers found that people who were taking a ...
A new weight loss drug target may help reduce appetite and burn calories without causing sickness, research suggests. The ...
Pemvidutide is a promising GLP-1/glucagon dual receptor agonist that focuses on fundamental metabolic processes to stimulate ...
Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer (EO-CRC) in patients with diabetes regardless of weight, according to a study ...
Just seven months after unveiling with $290 million, obesity biotech Metsera is back with another $215 million.
WEDNESDAY, Nov. 13, 2024 (HealthDay News) -- The blockbuster GLP-1 drug semaglutide ( Ozempic, Wegovy) could curb drinking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback